Ashton Thomas Private Wealth, LLC Halozyme Therapeutics, Inc. Transaction History
Ashton Thomas Private Wealth, LLC
- $2.62 Trillion
- Q1 2025
A detailed history of Ashton Thomas Private Wealth, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Ashton Thomas Private Wealth, LLC holds 4,170 shares of HALO stock, worth $226,973. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,170Holding current value
$226,973% of portfolio
0.01%Shares
7 transactions
Others Institutions Holding HALO
# of Institutions
595Shares Held
124MCall Options Held
320KPut Options Held
113K-
Black Rock Inc. New York, NY17.6MShares$959 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$698 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$329 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$212 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$200 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.58B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...